Evidence map›Paper›PMID 39754832›Full record

ArticleVaccine2025

Trends in costs of routinely recommended vaccines in the United States, 2001-2023.

RajReni Kaul, Andrew J Leidner, Harrell W Chesson

Abstract read
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

RajReni KaulNational Center for Immunization and Respiratory Diseases, CDC, USA.
Andrew J LeidnerNational Center for Immunization and Respiratory Diseases, CDC, USA. Electronic address: aleidner@cdc.gov.
Harrell W ChessonNational Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

objectivesEconomic models assessing vaccinations commonly assume that inflation-adjusted vaccine costs are constant over time. This study assessed this assumption using historical vaccine cost data.

methodsPrivate sector and CDC contracted vaccine cost data (2001-2023) were collected from the CDC Vaccine Price List and converted to US$2023 to adjust for inflation. Trends in inflation-adjusted costs were described, and the annual percent changes in costs were calculated for each vaccine.

resultsChanges in cost varied by vaccine. The average inflation-adjusted private sector costs increased by 0.9 % (IQR: -0.4 %-2.6 %) and 1.4 % (IQR: -0.4 %-3.2 %) annually among pediatric and adult vaccines, respectively, while CDC contracted costs increased by 0.9 % (IQR: 0.2 %-1.2 %) and 1.0 % (IQR: -0.8 %-2.1 %) annually among pediatric and adult vaccines, respectively.

conclusionsInflation-adjusted vaccine costs increased on average since 2001, highlighting limitations of constant cost assumptions. These findings can inform cost-effectiveness analyses of multi-year vaccination programs and policies.

Indexed as

Health Care CostsVaccinationVaccinesAdultCenters for Disease Control and Prevention, U.S.Cost-Benefit AnalysisHumansModels, EconomicUnited StatesVaccinesCost-effectiveness analysis methodsUnited StatesVaccine cost

Identifiers

PMID39754832
PMCPMC11822687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.